Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)

POMDOCTOR LIMITED (Nasdaq: POM) received a delisting notice from Nasdaq due to its ADS price falling below $1.00 for 30 consecutive days. The company is ineligible for a compliance period due to a recent reverse stock split. POM plans to appeal the decision by October 13, 2026, to avoid suspension and delisting.

Ultragenyx sold its Rare Pediatric Disease Priority Review Voucher for $210M, earned for Genglycos. Viatris agreed to acquire Pacira BioSciences for $1.65B, adding non-opioid pain therapies. Peter Young notes improving financing and M&A activity in biopharma despite policy and patent challenges.

Ultragenyx Pharmaceutical agreed to sell a rare pediatric disease priority review voucher for $210M, according to the company. The voucher was earned after FDA approval of Genglycos, a treatment for glycogen storage disease type Ia. The deal is subject to regulatory clearance and will provide non-dilutive capital for Ultragenyx's rare disease programs.

Ultragenyx Pharmaceutical will sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was earned after FDA approval of Genglycos, a treatment for glycogen storage disease type Ia. The sale will provide non-dilutive capital to advance Ultragenyx's pipeline and move toward profitability, continuing a cycle of voucher monetization for development funding.

H.C. Wainwright reiterated a Buy rating and $25 price target on Ultragenyx (RARE) after its sale of a priority review voucher for $210M. The company's stock is down 52% over the past year. Ultragenyx also received FDA approval for FAYUVI, its gene therapy for Sanfilippo syndrome Type A, marking its second gene therapy approval.

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The PRV was received after FDA approval of Genglycos, a treatment for glycogen storage disease type Ia (GSDIa).